Crossmark

Differences between men who have sex with men that use drugs and engage in chemsex and those who do not engage in chemsex in the French ANRS-PREVENIR cohort: the need to rethink harm reduction services

Crossref DOI link: https://doi.org/10.1186/s13011-025-00661-x

Published Online: 2025-08-25

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Sagaon-Teyssier, Luis

Hoyer, Maxime

Donadille, Cécile

Sow, Abdourahmane

Assoumou, Lambert

Ghosn, Jade

Costagliola, Dominique

Spire, Bruno

Molina, Jean-Michel

Protiere, Christel

Roux, Perrine
License Information

Text and Data Mining valid from 2025-08-25

Version of Record valid from 2025-08-25
More Information

Article History

Received: 31 October 2024

Accepted: 30 June 2025

First Online: 25 August 2025

Declarations

:

: The protocol was approved by the French Drug Agency (Agence nationale de sécurité du médicament et des produits de santé) and by the CPP Paris Ile de France IV ethics committee. All participants provided written informed consent.

: Not applicable.

: The authors declare the following financial interests, personal and/or professional relationships which may be considered as potential competing interests: • DC reports an HIV grant from Janssen (2019-2020), personal fees from Gilead (2020) and Pfizer (2022) for lectures outside the submitted work. • JG reports receiving supports as an advisor for Gilead Sciences, Merck, Janssen, Roche, AstraZeneca, Theratechnologies, and ViiV, and grants from Gilead Sciences an ViiV. • JMM reports receiving support as an advisor for Gilead Sciences, Merck, Janssen, and ViiV, and research grants from Gilead Sciences. • All other authors declare no conflict of interest.

Document is current

Any future updates will be listed below